

AbbVie Inc. (ABBV) - ANALYST REPORT

Executive Summary with Comprehensive Analysis

\$201.55 **-\$1.16 (-0.57%)** AS OF 2026-05-08

Strategy: Conservative Stop Loss (Fixed ATR-based)

■ QUICK DECISION

Action: HOLD | Confidence: LOW | Signal Strength: 0/7

EXECUTIVE SUMMARY - Essential Metrics

TECHNICAL METRICS	VALUE	FUNDAMENTAL METRICS	VALUE
Current Price	\$201.55	Market Cap	\$356.5B
Past Win Rate (Backtest)	55.6%	Forward P/E	12.4x
Past Total Return	+39.9%	Analyst Target	\$252.23
RSI / Trend Strength	43 / 14	Upside to Target	+25.1%
MACD Signal	Bearish	Revenue Growth	+12.4%
Profit Factor	2.66	Institutional Own.	79.9%
Position Entry	2026-04-29 @ \$203.89	Analyst Ratings	21 Buy / 9 Hold / 1 Sell
Open Position Past P&L	-1.1%		

■ TECHNICAL ANALYSIS SUMMARY

Indicator	Value	Signal
EMA 20	\$205.08	Bearish
EMA 50	\$209.41	Bearish
RSI (14)	43.2	Neutral range
Trend Strength (ADX)	14.5	Weak/No trend (<20)

■ CONSENSUS & INVESTMENT RATIONALE

RATING	BUY
Target Price	\$252.23
Upside/Downside	+25.1%
Risk/Reward	1.68:1
Time Horizon	6-12 months

Investment Rationale: Our BUY rating is based on: (1) Technical backtest showing 55.6% win rate with +39.9% total return over backtest period, (2) +25.1% upside to analyst consensus target of \$252.23, (3) Moderate fundamental growth profile with +12.4% revenue growth, and (4) 79.9% institutional ownership indicating high conviction from professional investors.

Action: Maintain position with -1.1% unrealized gain. Watch for confluence signal to add.

Technical Signal: Confluence 0/7 (threshold: 5) | **Risk/Reward:** Neutral

■ KEY INSIGHT

The fixed stop strategy has proven effective (Win Rate: 55.6%, Avg Return: +5.7%), but patience is critical. Only enter on confirmed signals with proper risk management. Current technical confluence of 0 does not meet entry threshold of 5 - remain on sidelines. Fundamental backdrop shows -46% earnings growth with 80% institutional ownership, indicating strong conviction from professional investors.

■ INTELLIGENT STOP LOSS STRATEGY

METRIC	VALUE	DETAILS
Current Price	\$201.55	Latest market price
Buy Stop Loss	\$190.97	Conservative 2.0x ATR (5.2% distance)
Position Stop Loss	\$188.33	Hybrid 2.50x ATR (6.6% distance)
ATR (14-day)	\$5.29	Volatility: 2.6% of price
ADX Strength	14.5	Weak/No Trend

Status: Position down -1% - Wider stops for recovery

ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong

■ Strategy Comparison: Conservative vs Hybrid

METRIC	CONSERVATIVE (2.0x ATR)	HYBRID (Adaptive)
Past Win Rate	56%	56%
Past Total Return	+39.9%	+39.9%
Max Drawdown	-16.1%	-16.1%
Total Trades	18	18
Position	OPEN	OPEN

Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit.

For the latest stock analysis, support, resistance and interactive charts, visit [Ultra Stock Analysis Pro](#)

■ ANALYST RATING CHANGES - COMPLETE HISTORY

All recent upgrades, downgrades, and price target changes (last 90 days)

Firm	Action	From → To	Date
Guggenheim	REITERATED	Buy → Buy	May 01, 2026
Cantor Fitzgerald	REITERATED	Overweight → Overweight	Apr 30, 2026
Canaccord Genuity	INITIATED	Buy	Apr 21, 2026
RBC Capital	INITIATED	Outperform	Feb 25, 2026
Barclays	INITIATED	Overweight	Feb 20, 2026

Analyst Price Targets

Average Target: \$252.23 (+25.1% from current)

High Target: \$328.00 (+62.7%)

Low Target: \$184.00 (-8.7%)

Current Price: \$201.55

DETAILED ANALYSIS: BUY-SIDE PERSPECTIVE

In-Depth Portfolio Management Analysis

Expected Returns & Position Sizing

Based on backtest performance (Win Rate: 55.6%, Avg Return: +5.7%) and analyst consensus (Target: \$252.23, +25.1% upside), an **OVERWEIGHT** exposure may be considered. Risk/Reward ratio of 1.68:1 suggests moderate risk-adjusted returns. Current open position shows -1.1% unrealized gain, supporting review decision.

Catalyst Calendar & Timing

Next Major Catalyst: Jul 30, 2026 earnings report

Seasonality: Historical analysis shows positive momentum in backtest period

Technical Setup: Neutral - waiting for confluence signal

Institutional Activity: 79.9% institutional ownership (Largest: Vanguard Group Inc)

Short Interest: 1.4% of float - Moderate short interest

Liquidity Profile

Average Volume: 6.9M shares/day - Lower liquidity

Market Cap: \$356.5B - Large cap

Beta: 0.30 - Lower than market volatility

Execution Risk: Moderate for institutional-sized positions

SELL-SIDE PERSPECTIVE - Investment Research Analysis

Investment Thesis

AbbVie Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 12.4x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 31.6% shows strong profitability. **Fundamental Outlook:** Moderate Growth - Monitoring profitability amid revenue expansion

Valuation Analysis

Forward P/E: 12.4x

Trailing P/E: 98.8x

Price/Sales: 5.67x - Premium valuation

Price/Book: -108.95x

Enterprise Value: \$419.6B

EV/Revenue: 6.68x (vs industry avg)

Competitive Positioning & Market Share

Key Competitors: Various industry players

U.S. Market Share: 0% - Competitive player

Global Market Share: 0%

Competitive Advantages: Market position, Technology, Brand

Key Products: Core products and services

Institutional Sentiment & Ownership

Institutional Ownership: 79.9% - Very high institutional confidence

Largest Holder: Vanguard Group Inc (180.8M shares)

Analyst Coverage: 31 analysts

Consensus: 21 Buy, 9 Hold, 1 Sell - Bullish sentiment

■ 7-DAY NEWS SENTIMENT ANALYSIS

Market Sentiment from Recent Financial News

METRIC	VALUE	ANALYSIS
Overall Score	+4.1 / 10	Bullish
Articles Analyzed	10	Last 7 days (top 5 shown per category)
Bullish Articles	6 (60%)	Positive sentiment
Bearish Articles	0 (0%)	Negative sentiment
Neutral Articles	4 (40%)	Mixed/Neutral tone

■ TOP BULLISH HEADLINES

1. **AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting** (MarketBeat, May 09)

AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-...

Source: <https://www.marketbeat.com/instant-alerts/abbvie-touts-record-sales-and-pipeline>

2. **AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner** (Insider Monkey, May 08)

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named ...

Source: <https://finance.yahoo.com/sectors/healthcare/articles/abbvie-abbv-admare-bioinno>

3. **Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity** (24/7 Wall St., May 07)

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors' shortlists. Both e...

Source: <https://247wallst.com/investing/2026/05/07/vanguard-high-dividend-yield-etf-deli>

4. **AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.** (Barchart, May 07)

Q1 earnings show this Dividend King still looks built for the long term....

Source: <https://www.barchart.com/story/news/1781867/abbvie-delivers-strong-q1-earnings-b>

5. **Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?** (Simply Wall St., May 07)

In recent weeks, AbbVie reported first-quarter 2026 revenue of US\$15,002 million, while also securing new Canadian formulary listings and reimbursemen...

Source: <https://finance.yahoo.com/sectors/healthcare/articles/does-strong-q1-results-sky>

■ SENTIMENT INTERPRETATION

The news sentiment is **strongly bullish**, indicating positive market perception and favorable coverage. This suggests growing investor confidence and potential upward momentum. Consider this as a supporting factor for bullish positions, but verify with technical and fundamental analysis.

DEEP DIVE: COMPREHENSIVE RISK ASSESSMENT

Detailed Risk Factors and Mitigation Strategies

Key Risks & Mitigants

Company-Specific Risks:

- Competition
- Market conditions
- Regulatory changes

Technical Risk Factors:

- Win Rate: 55.6% (10 wins, 8 losses)
- Profit Factor: 2.66x (Avg Win 14.6% vs Avg Loss -5.5%)
- Current Confluence: 0 (Last: 5 on Apr 29) - No setup - awaiting signal
- Volatility (ATR 14): \$5.29 (2.6% of price) - Stop loss typically 2-3x ATR

Market Risk:

- Beta: 0.30 - Below-average market sensitivity
- Short Interest: 1.4% - Normal short activity

REFERENCE: APPENDIX A - Complete Technical Indicators

Comprehensive Technical Data for Quantitative Analysis

Indicator	Value	Interpretation
EMA 20	\$205.08	Short-term trend
EMA 50	\$209.41	Medium-term trend
EMA 200	\$210.26	Long-term trend
Relative Strength	43.2	Neutral range
MACD	-1.67	Bearish
MACD Signal	-2.06	Signal line
MACD Histogram	0.40	Bullish
Volatility (ATR 14)	\$5.29	2.6% of price
Trend Strength (ADX)	14.5	Weak/No trend (<20)
+DI	23.1	Positive directional movement
-DI	24.6	Negative directional movement
Stochastic %K	51.2	Neutral
Stochastic %D	57.9	Neutral
Bollinger Upper	\$212.46	Resistance zone
Bollinger Middle	\$204.43	Moving average
Bollinger Lower	\$196.39	Support zone
VWAP	\$201.32	Volume-weighted average

REFERENCE: APPENDIX B - Complete Fundamental Metrics

Comprehensive Fundamental Data for Financial Analysis

Category	Metric	Value	Interpretation
Valuation	Market Cap	\$356.5B	Total market value
Valuation	Enterprise Value	\$419.6B	Total company value
Valuation	Forward P/E	12.4x	Price to forward earnings
Valuation	Trailing P/E	98.8x	Price to trailing earnings
Valuation	PEG Ratio	0.56	P/E relative to growth
Valuation	Price/Sales	5.67x	Market cap to revenue
Valuation	Price/Book	-108.95x	Price to book value
Valuation	EV/Revenue	6.68x	Enterprise value to revenue
Valuation	EV/EBITDA	14.0x	Enterprise value to EBITDA
Performance	Revenue (TTM)	\$62.8B	Trailing 12-month revenue
Performance	Revenue Growth	+12.4%	Year-over-year growth
Performance	Earnings Growth	-45.8%	Earnings growth rate
Performance	EPS Growth (Next Yr)	+694.5%	Forward EPS growth estimate
Performance	Gross Profit	\$45.2B	Revenue minus COGS
Performance	Operating Income	\$0.0B	EBIT
Performance	Net Income	\$3.6B	Bottom line profit
Performance	Free Cash Flow	\$0.0B	Cash after capex
Performance	Operating Cash Flow	\$0.0B	Cash from operations
Profitability	Gross Margin	72.0%	Gross profit margin
Profitability	Operating Margin	31.6%	Operating efficiency
Profitability	Profit Margin	5.8%	Net margin
Profitability	ROE	0.0%	Return on equity
Profitability	ROA	0.0%	Return on assets
Profitability	ROIC	N/A	Return on invested capital
Balance Sheet	Total Assets	\$0.0B	Total assets
Balance Sheet	Total Liabilities	\$0.0B	Total liabilities
Balance Sheet	Total Debt	\$68.4B	Total debt outstanding
Balance Sheet	Cash & Equivalents	\$5.3B	Liquid assets
Balance Sheet	Book Value/Share	-\$1.85	Net worth per share
Balance Sheet	Current Ratio	0.00	Current assets/liabilities
Balance Sheet	Quick Ratio	0.00	Liquid assets/liabilities
Balance Sheet	Debt/Equity	0.00	Leverage ratio
Market	Beta	0.30	Market correlation
Market	52-Week High	\$244.81	Annual high
Market	52-Week Low	\$176.57	Annual low

Market	Avg Volume	6.9M	Average daily volume
Market	Shares Outstanding	1.8B	Total shares
Market	Float	1.8B	Tradeable shares
Market	Short Interest	1.4%	Shares sold short
Market	Institutional Own.	79.9%	Institution held
Analysts	Coverage Count	30	Number of analysts
Analysts	Average Rating	1.8	1=Strong Buy, 5=Sell
Analysts	Buy/Hold/Sell	21/9/1	Rating distribution
Analysts	Target Price	\$252.23	Average price target
Analysts	Target High	\$328.00	Highest target
Analysts	Target Low	\$184.00	Lowest target
Other	Next Earnings	Jul 30, 2026	Earnings report date
Other	Dividend Yield	3.43%	Annual dividend rate
Other	Ex-Dividend Date	1776211200	Next ex-div date

REFERENCE: APPENDIX C - Complete Trade History

Detailed Backtesting Results and Trade Log

Entry	Exit	Type	Entry \$	Exit \$	Past P&L %	Past P&L \$
2019-05-21	2019-05-31	GOLDEN_CROSS	\$60.24	\$57.13	-5.2%	\$-242
2019-08-07	2020-03-13	CONFLUENCE	\$48.74	\$66.37	+36.2%	\$+1411
2020-05-12	2021-09-01	CONFLUENCE	\$71.38	\$94.11	+31.8%	\$+955
2021-09-07	2021-09-08	CONFLUENCE	\$91.40	\$92.51	+1.2%	\$+61
2021-11-02	2022-05-23	CONFLUENCE	\$98.87	\$127.97	+29.4%	\$+2038
2022-07-07	2022-08-04	GOLDEN_CROSS	\$131.41	\$121.22	-7.8%	\$-458
2022-09-30	2023-01-24	CONFLUENCE	\$117.11	\$131.42	+12.2%	\$+630
2023-03-03	2023-03-09	GOLDEN_CROSS	\$138.87	\$131.12	-5.6%	\$-465
2023-06-01	2023-08-16	CONFLUENCE	\$119.84	\$137.61	+14.8%	\$+906
2023-09-14	2023-10-05	CONFLUENCE	\$139.51	\$133.89	-4.0%	\$-388
2023-10-19	2023-11-14	CONFLUENCE	\$133.46	\$126.61	-5.1%	\$-424
2023-12-11	2024-04-16	GOLDEN_CROSS	\$138.70	\$151.89	+9.5%	\$+805
2024-04-26	2024-07-01	CONFLUENCE	\$149.17	\$159.21	+6.7%	\$+432
2024-07-25	2024-11-13	CONFLUENCE	\$171.80	\$161.94	-5.7%	\$-385
2025-01-22	2025-04-10	CONFLUENCE	\$162.36	\$167.16	+3.0%	\$+202
2025-09-11	2025-09-22	CONFLUENCE	\$215.11	\$217.43	+1.1%	\$+90
2025-09-30	2025-11-05	CONFLUENCE	\$226.17	\$213.27	-5.7%	\$-606
2025-11-12	2026-01-14	CONFLUENCE	\$229.46	\$218.31	-4.9%	\$-324
2026-04-29	OPEN	CONFLUENCE	\$203.89	OPEN	-1.1%	\$-56

IMPORTANT DISCLAIMER

Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-05-08. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.

Next Earnings: Jul 30, 2026

Report Generated: May 09, 2026 at 12:52 PM